Denali Therapeutics Statistics Share Statistics Denali Therapeutics has 146.21M
shares outstanding. The number of shares has increased by 1.59%
in one year.
Shares Outstanding 146.21M Shares Change (YoY) 1.59% Shares Change (QoQ) 0.64% Owned by Institutions (%) 75.76% Shares Floating 131.98M Failed to Deliver (FTD) Shares 7,620 FTD / Avg. Volume 0.4%
Short Selling Information The latest short interest is 13.08M, so 8.95% of the outstanding
shares have been sold short.
Short Interest 13.08M Short % of Shares Out 8.95% Short % of Float 10.01% Short Ratio (days to cover) 5.54
Valuation Ratios The PE ratio is -7.93 and the forward
PE ratio is -5.45.
Denali Therapeutics's PEG ratio is
-0.06.
PE Ratio -7.93 Forward PE -5.45 PS Ratio 0 Forward PS 26 PB Ratio 2.73 P/FCF Ratio -9.22 PEG Ratio -0.06
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Denali Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 8.46,
with a Debt / Equity ratio of 0.04.
Current Ratio 8.46 Quick Ratio 8.46 Debt / Equity 0.04 Debt / EBITDA -0.12 Debt / FCF -0.13 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-954.34K Employee Count 443 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 68K Effective Tax Rate -0.02%
Stock Price Statistics The stock price has increased by -46.14% in the
last 52 weeks. The beta is 1.29, so Denali Therapeutics's
price volatility has been higher than the market average.
Beta 1.29 52-Week Price Change -46.14% 50-Day Moving Average 14.39 200-Day Moving Average 16.11 Relative Strength Index (RSI) 62.72 Average Volume (20 Days) 1,911,323
Income Statement
Revenue n/a Gross Profit n/a Operating Income -487.34M Net Income -422.77M EBITDA -414.91M EBIT -422.7M Earnings Per Share (EPS) -2.57
Full Income Statement Balance Sheet The company has 174.96M in cash and 48.71M in
debt, giving a net cash position of 126.25M.
Cash & Cash Equivalents 174.96M Total Debt 48.71M Net Cash 126.25M Retained Earnings -1.54B Total Assets 1.17B Working Capital 843.65M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -347.69M
and capital expenditures -15.91M, giving a free cash flow of -363.61M.
Operating Cash Flow -347.69M Capital Expenditures -15.91M Free Cash Flow -363.61M FCF Per Share -2.21
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
